STING1 and neoplasm: Since pre‐existing cytotoxic T cell activation and infiltration into the TME is important for ICIs to work properly, the potential synergism between STING agonists and ICIs lies firstly in their capacity to increase type I IFNs and thereby T cell infiltration, and secondly, in blocking checkpoints on immune cells potentially upregulated by the tumor and STING agonists.